#USA #Anixa Biosciences #San Jose #CAR-T #Ovarian Cancer

Anixa Biosciences Highlights Ovarian Cancer CAR-T Trial at ESMO 2025

On June 9, 2025, Anixa Biosciences, Inc. announced an exciting development in their fight against cancer. The company, a publicly traded entity under the NASDAQ ticker ANIX, focuses on innovative solutions for the treatment and prevention of various forms of cancer. In a significant showcase of their progress, Anixa revealed that Dr. Robert Wenham will present an e-poster at the upcoming European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress taking place from June 19 to June 21, 2025, in the beautiful city of Vienna, Austria.

Details of the Presentation

Dr. Wenham, who leads the Gynecologic Oncology Program at Moffitt Cancer Center and serves as the principal investigator for Anixa's Phase 1 clinical trial on ovarian cancer CAR-T immunotherapy, will present critical findings. The title of the e-poster is, "Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA)." Notably, this presentation is listed as Poster No. 145eTiP and promises to offer insights into Anixa's unique methodological innovations in treating recurrent ovarian cancer.

Innovative CAR-T Technology

At the core of Anixa's groundbreaking approach is a novel CAR-T technology referred to as chimeric endocrine receptor-T cell (CER-T) therapy. Unlike traditional CAR-T therapies, which typically use antibody fragments, this method utilizes the natural ligand of the FSHR receptor—FSH itself. This innovative approach allows the therapy to bind directly to the tumor cells, potentially enhancing the specificity and effectiveness of the treatment. The development of this technology is in collaboration with the prestigious Moffitt Cancer Center, known for its pioneering work in the field of cancer immunotherapy.

The Role of Moffitt Cancer Center

Moffitt Cancer Center's world-class reputation in the domain of cancer treatments strengthens Anixa's initiatives. The center has been at the forefront of cancer immunotherapy, making strides with next-generation cell therapies, including CAR-T and tumor-infiltrating lymphocyte (TIL) therapies. Together, they aim to harness the immune system's potential to combat cancer more effectively.

Expanding Cancer Vaccine Portfolio

In addition to its CAR-T research, Anixa is also developing a series of vaccines aimed at preventing and treating breast and ovarian cancers in conjunction with the Cleveland Clinic. The collaboration has yielded vaccines targeting "retired" proteins associated with various malignancies. These advancements highlight Anixa's multifaceted approach to cancer treatment.

Emphasizing a Unique Business Model

Anixa Biosciences employs a distinctive business model that leverages partnerships with esteemed research institutions throughout the development process. This strategy allows the company to explore and integrate emerging technologies across several disciplines, continually enhancing its drug development pipeline. By collaborating with leaders in medical innovation, Anixa ensures a comprehensive approach to tackling some of the most challenging forms of cancer.

A Future-Oriented Perspective

As Anixa prepares for its presentation at one of the largest European conferences dedicated to oncology, it also embraces the forward-looking challenges in scientific research. The company acknowledges that such endeavors come with inherent uncertainties and risks but remains committed to advancing medical solutions that can significantly alter the landscape of cancer treatment.

This presentation marks a pivotal moment for Anixa Biosciences as it illuminates the future potential of CAR-T therapies in the treatment of ovarian cancer. Attendees at the ESMO Congress can look forward to insightful updates that could shape the direction of future oncology research and treatment strategies. To stay informed about Anixa's developments, visit their official website or follow them on social media platforms.